CLN2疾病的酶替代治疗:MRI体积测量显示脑体积丢失较自然病史队列显著减慢
本研究在1个英国中心对19例CLN2疾病患者(14女5男)进行系列3D T1加权MRI随访(1-9年),用FreeSurfer分割测量脑区体积,并与已发表的12例自然病史队列(8女4男)用相同方法再分析比较。结果显示治疗患者所有分割脑区的体积丢失均远慢于自然病史队列,例如幕上灰质年体积丢失治疗组平均3%(SD 0.74%)vs 自然病史队列平均16.8%(SD 1.5%),均P < .001。作者结论为自动MRI体积测量是监测CLN2患儿治疗反应的敏感工具。
要点
- CLN2疾病ERT治疗患者幕上灰质年体积丢失平均3%,自然病史队列平均16.8%(P < .001)。
- 所有分割脑区(幕上灰白质、深部灰质、侧脑室、小脑灰白质)体积丢失在治疗组均远慢于自然病史队列。
- 自动MRI体积测量(FreeSurfer)可作为监测CLN2患儿ERT治疗反应的敏感工具。
核心结论
- 治疗队列在多个解剖区域的脑实质体积丢失速率较自然病史队列显著减慢,结果与既往临床数据中ERT阳性反应互补,自动MRI体积测量是监测CLN2患儿治疗反应的敏感工具。
研究设计与样本
- 研究纳入1个英国中心的19例CLN2疾病患者(14女5男),采用系列3D T1加权MRI随访1-9年,用FreeSurfer进行脑分割,并与已发表的12例自然病史队列(8女4男)用相同方法再分析比较;体积随时间变化用线性混合效应模型分析,排除治疗开始前的扫描。
诊断标准与关键数值
- 测量指标包括幕上灰质和白质、深部灰质(基底节/丘脑)、侧脑室及小脑灰质和白质的体积;幕上灰质年体积丢失治疗组平均3%(SD 0.74%)(P < .001),自然病史队列平均16.8%(SD 1.5%)(P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Neuronal ceroid lipofuscinoses are a group of neurodegenerative disorders. Recently, enzyme replacement therapy (ERT) was approved for neuronal ceroid lipofuscinosis type 2 (CLN2), a subtype of neuronal ceroid lipofuscinoses. The aim of this study was to quantify brain volume loss in CLN2 disease in patients on ERT in comparison with a natural history cohort using MRI.
MATERIALS AND METHODS: Nineteen (14 female, 5 male) patients with CLN2 disease at 1 UK center were studied using serial 3D T1-weighted MRI (follow-up time, 1-9 years). Brain segmentation was performed using FreeSurfer. Volume measurements for supratentorial gray and white matter, deep gray matter (basal ganglia/thalami), the lateral ventricles, and cerebellar gray and white matter were recorded. The volume change with time was analyzed using a linear mixed-effects model excluding scans before treatment onset. Comparison was made with a published natural history cohort of 12 patients (8 female, 4 male), which was re-analyzed using the same method.
RESULTS: Brain volume loss of all segmented brain regions was much slower in treated patients compared with the natural history cohort. For example, supratentorial gray matter volume in treated patients decreased by a mean of 3% (SD, 0.74%) (P < .001) annually compared with an annual volume loss of a mean of 16.8% (SD, 1.5%) (P < .001) in the natural history cohort.
CONCLUSIONS: Our treatment cohort showed a significantly slower rate of brain parenchymal volume loss compared with a natural history cohort in several anatomic regions. Our results complement prior clinical data that found a positive response to ERT. We demonstrate that automated MRI volumetry is a sensitive tool to monitor treatment response in children with CLN2 disease.
引用
- Gaur P, Gissen P, Biswas A, et al. Enzyme Replacement Therapy for CLN2 Disease: MRI Volumetry Shows Significantly Slower Volume Loss Compared with a Natural History Cohort. AJNR Am J Neuroradiol. 2024. PMID: 38977290. doi:10.3174/ajnr.A8408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。